Company intelligence / Profile preview

Stablix Therapeutics

New York, New York, USAstablix.com ↗

Ownership: Private
Employees: ~100
Development stage: Preclinical

Overview

Stablix has developed a proprietary platform for targeted protein stabilization by recruiting deubiquitinases to remove ubiquitin from specific proteins. This approach aims to restore or enhance the function of disease-relevant proteins. The company’s lead programs are advancing toward clinical studies but have not yet reported clinical results as of early/mid–2024.

Therapeutic areas: OncologyImmunologyRare Diseases
Modalities: Small molecules (heterobifunctional small molecules called RESTORACS)Proteins (targeted protein stabilization)
Industry: Biotech

Partnerships

Vertex Pharmaceuticals Incorporated – strategic collaboration and license agreement focused on discovering/developing novel TPS therapeutics using the RESTORED platform for multiple disease targetsVersant VenturesNew Enterprise Associates (NEA)Cormorant Asset ManagementEuclidean CapitalAlexandria Venture Investments

Beyond the preview

Go deeper on Stablix Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Stablix Therapeutics.

Explore the full profile